158 related articles for article (PubMed ID: 38649821)
1. Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer.
Lee J; Kim EA; Kang J; Chae YS; Park HY; Kang B; Lee SJ; Lee IH; Park JY; Park NJ; Jung JH
BMC Mol Cell Biol; 2024 Apr; 25(1):12. PubMed ID: 38649821
[TBL] [Abstract][Full Text] [Related]
2. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
5. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells.
Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA
Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390
[TBL] [Abstract][Full Text] [Related]
7. Curcumin attenuates lncRNA H19‑induced epithelial‑mesenchymal transition in tamoxifen‑resistant breast cancer cells.
Cai J; Sun H; Zheng B; Xie M; Xu C; Zhang G; Huang X; Zhuang J
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179087
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance.
Sun W; Xu X; Jiang Y; Jin X; Zhou P; Liu Y; Guo Y; Ma D; Zuo W; Huang S; He X; Shao Z
Int J Cancer; 2019 Aug; 145(3):842-856. PubMed ID: 30720865
[TBL] [Abstract][Full Text] [Related]
9. LncRNA SOX2OT affects cervical cancer cell growth, migration and invasion by regulating SOX2.
Chang X; Zhang H; Yang Q; Pang L
Cell Cycle; 2020 Jun; 19(11):1391-1403. PubMed ID: 32286144
[TBL] [Abstract][Full Text] [Related]
10. MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells.
Kim S; Jeon M; Lee JE; Nam SJ
Oncol Rep; 2016 Apr; 35(4):2398-404. PubMed ID: 26780941
[TBL] [Abstract][Full Text] [Related]
11. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy.
Wang J; Xie S; Yang J; Xiong H; Jia Y; Zhou Y; Chen Y; Ying X; Chen C; Ye C; Wang L; Zhou J
J Hematol Oncol; 2019 Jul; 12(1):81. PubMed ID: 31340867
[TBL] [Abstract][Full Text] [Related]
12. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.
Phuong NT; Kim SK; Lim SC; Kim HS; Kim TH; Lee KY; Ahn SG; Yoon JH; Kang KW
Breast Cancer Res Treat; 2011 Nov; 130(1):73-83. PubMed ID: 21170675
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro.
Hawsawi Y; Humphries MP; Wright A; Berwick A; Shires M; Al-Kharobi H; El-Gendy R; Jove M; Twelves C; Speirs V; Beattie J
Oncotarget; 2016 May; 7(22):32129-43. PubMed ID: 27050076
[TBL] [Abstract][Full Text] [Related]
14. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer.
Ma T; Liang Y; Li Y; Song X; Zhang N; Li X; Chen B; Zhao W; Wang L; Yang Q
Cell Signal; 2020 Apr; 68():109536. PubMed ID: 31927036
[TBL] [Abstract][Full Text] [Related]
15. Role of monocarboxylate transporter I/lactate dehydrogenase B-mediated lactate recycling in tamoxifen-resistant breast cancer cells.
Choi MC; Kim SK; Choi YJ; Choi YJ; Kim S; Jegal KH; Lim SC; Kang KW
Arch Pharm Res; 2023 Dec; 46(11-12):907-923. PubMed ID: 38048029
[TBL] [Abstract][Full Text] [Related]
16. PI3-kinase/p38 kinase-dependent E2F1 activation is critical for Pin1 induction in tamoxifen-resistant breast cancer cells.
Lee KY; Lee JW; Nam HJ; Shim JH; Song Y; Kang KW
Mol Cells; 2011 Jul; 32(1):107-11. PubMed ID: 21573702
[TBL] [Abstract][Full Text] [Related]
17. SOX4-mediated FBW7 transcriptional upregulation confers Tamoxifen resistance in ER+ breast cancers via GATA3 downregulation.
Sharma A; Thacker G; Mishra M; Singh AK; Upadhyay V; Sanyal S; Trivedi AK
Life Sci; 2022 Aug; 303():120682. PubMed ID: 35662647
[TBL] [Abstract][Full Text] [Related]
18. HOXB5 Confers Tamoxifen Resistance in Breast Cancer Cells and Promotes Tumor Aggression and Progression.
Kim CY; Kim YC; Oh JH; Kim MH
Anticancer Res; 2021 Jul; 41(7):3409-3417. PubMed ID: 34230136
[TBL] [Abstract][Full Text] [Related]
19. Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
Tan S; Ding K; Chong QY; Zhao J; Liu Y; Shao Y; Zhang Y; Yu Q; Xiong Z; Zhang W; Zhang M; Li G; Li X; Kong X; Ahmad A; Wu Z; Wu Q; Zhao X; Lobie PE; Zhu T
J Biol Chem; 2017 Aug; 292(33):13551-13564. PubMed ID: 28637868
[TBL] [Abstract][Full Text] [Related]
20. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
